Products

Agomelatin is the world's first melatonin receptor MT1 and MT2 agonist antidepressant, developed by The French company Schveal, for the treatment of adult patients with major depressive episodes.  We know that melatonin is a kind of endogenous neural hormone, only at night is produced by the pineal gland secretion of pituitary, and concentrated in hypothalamic suprachiasmatic nucleus (SCN) of melatonin receptor, participate in the mediation of mammalian circadian rhythms, guardians are known in time, correcting the diurnal cycle to adjust clock from outside.  However, because of its high catabolic Chemicalbook in vivo, melatonin has a short half-life and poor selectivity to its receptors in SCN, which results in its limited use in the treatment of circadian rhythm disorders.  Therefore, to overcome these deficiencies of melatonin, researchers designed a series of melatonin analogues.  Molecular model studies showed that the indole-ring of melatonin was the structural site of catabolism inactivation, so the indole-ring became the ideal site for electron isometric modification.  Agomelatine developed by Sivea is a naphthalene biological (electronic) isosomal analogue of melatonin, which replaces the indole ring with a naphthalene nucleus, making it more metabolically stable than melatonin.